Article info
PDFEpidemiology
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
- Correspondence to Professor Daniel Aletaha, Department of Medicine III, Division of Rheumatology, Medical University of Vienna, 1090 Vienna, Austria; daniel.aletaha{at}meduniwien.ac.at
Citation
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
Publication history
- Received May 13, 2021
- Accepted July 12, 2021
- First published July 20, 2021.
Online issue publication
September 13, 2021
Article Versions
- Previous version (20 July 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage